Table 2.
Information of vaccine used in the eligible studies and the immunogenicity.
| GMT |
|||||||
|---|---|---|---|---|---|---|---|
| First Author | vaccine formation | vaccine strains | dosage (ug) | interval between the first and the boost dose | one dose | booster dose | fold increase in GMT |
| Beyer | split trivalent vaccine | A/Chile/1/83(H1N1) | 15 | 30 days | NA | NA | NA |
| A/Pilippines/2/82(H3N2) | 15 | NA | NA | NA | |||
| B/USSR/100/83 | 15 | NA | NA | NA | |||
| Vogtlander | subunit trivalent vaccine | A/Beijing/262/95(H1N1) | 15 | 56 days | 46 | 53.4 | 0.16 |
| A/Sydney/5/97(H3N2) | 15 | 36.4 | 60.9 | 0.67 | |||
| B/Beijing/184/93 | 15 | 46 | 47.2 | 0.03 | |||
| Tanzi | subunit trivalent | A/NewCaledonia/20/99 (H1N1) | 15 | 30 days | 52 | 61.5 | 0.18 |
| MF59-adjuvanted vaccine | A/Panama/2007/99(H3N2) | 15 | 44 | 49 | 0.11 | ||
| B/HongKong/330/2001 | 15 | 26.3 | 27.9 | 0.06 | |||
| Song | split trivalent vaccine | A/New Caledonia/20/99 (H1N1) | 15 | 28 days | 21.54 | 24.28 | 0.13 |
| A/Moscow/10/99 (H3N2) | 15 | 37.13 | 64.09 | 0.73 | |||
| B/HongKong/330/2001 | 15 | 25.62 | 21.14 | 0.83 | |||
| Scharpe (2009) | split trivalent vaccine | A/New Caledonia/20/99 (H1N1) | 15 | 90 days | NA | NA | NA |
| A/Panama/2007/99 (H3N2) | 15 | NA | NA | NA | |||
| B/Shangdong/7/97 | 15 | NA | NA | NA | |||
| Scharpe (2008) | split trivalent vaccine | A/New Caledonia/20/99 (H1N1) | 15 | 90 days | NA | NA | NA |
| A/Panama/2007/99 (H3N2) | 15 | NA | NA | NA | |||
| B/Shangdong/7/97 | 15 | NA | NA | NA | |||
| Quintana | split monovalent | A%California%7% 2009(H1N1) | 3.75 | 21 days | 95.5 | 124.9 | 0.31(HD) |
| AS03A-adjuvanted vaccine | 344.5 | 350.2 | 0.01(PD) | ||||
| 31.8 | 46.5 | 0.46(RT) | |||||
| Brakemeier | split monovalent AS03A-adjuvanted vaccine | A%California%7%2009(H1N1) | 3.75 | 21 ± 3.5 days | 46.3 | 67.4 | 0.46 |
| Le Corre | split monovalent vaccine | A%California%7%2009(H1N1 | 15 | 21 days | 47.6 | 59 | 0.23 |
Note. GMT, Geometric Mean Titer; NA, not available.